Table 2.
Identified events of within-patient acquired resistance.
|
Isolate ID |
HIV |
Treatment history |
Mutation |
Acquired resistance |
|---|---|---|---|---|
|
107 |
- |
follow-up (ETH* treated) |
ethA L225fs |
ETH |
|
108 |
- |
follow-up (ETH and FLQ treated) |
ethA S208P |
ETH |
|
516 |
- |
follow-up (unknown treatment) |
pncA D129G |
PZA |
|
1757 |
- |
follow-up (ETH and FLQ treated) |
ethA H22P |
ETH |
|
2098 |
- |
follow-up (ETH and FLQ treated) |
ethA F302S + gyrB D461V |
ETH + FLQ |
|
2485 |
- |
follow-up (unknown treatment) |
ethA G437fs |
ETH |
|
POGU |
- |
follow-up (ETH and FLQ treated) |
ethA R259fs + gyrB R292G |
ETH + FLQ |
|
110 |
+ |
follow-up (ETH and FLQ treated) |
gyrB R446S |
FLQ |
|
257 |
+ |
follow-up (ETH and FLQ treated) |
inhA -15 C>T |
ETH |
|
1298 |
+ |
follow-up (ETH and FLQ treated) |
gyrA D94N |
FLQ |
|
2569 |
+ |
follow-up (ETH treated) |
ethA S251fs |
ETH |
*Patient received the ETH analogue prothionamide.